ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ LYMPHÔM KHÔNG HODGKIN TẾ BÀO B BẰNG PHÁC ĐỒ R-CHOP TẠI BỆNH VIỆN UNG BƯỚU THÀNH PHỐ CẦN THƠ NĂM 2021 – 2023

Abstract

Background: Non-Hodgkin's lymphoma (NHL) is a type of cancer originating from lymphatic system with primary lesions most commonly found in lymph nodes or extranodal sites such as stomach, intestine, lung, bone, breast... Chemotherapy is the core in treatment for Non-Hodgkin's lymphoma with  greatest importance and high efficiency. Currently, the standard regimen recommended by the World Health Organization for B-cell Non-Hodgkin's lymphoma with CD20-positive is R-CHOP, which consists of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus Rituximab. However, treatment toxicity also needs attention.Therefore, the study has been proposed to evaluate the results of the R-CHOP regimen. Objectives: To describe clinical, subclinical characteristics and assess the results of B-cell Non-Hodgkin's lymphoma patients receiving R-CHOP chemotherapy regimen at Can Tho Oncology Hospital 2021-2023. Materials and method: A prospective study, case series, conducted on 32 B-cell Non-Hodgkin's lymphoma patients with CD20(+), treated with the R-CHOP regimen for 4 cycles or until disease progression during treatment or intolerance of side effects. Results: Sex: male/female =0.88. Average age: 55.72 ± 12.45. PS  0-1 proportion: 65.6%. Time  from onset ≤ 3 months is 65.6%. Lymph node was the first recorded lesion with the rate of 43.8%. Bulky lymph node (≥10cm) accounted for 18.8%. increased LDH accounted for 21.9%. Diffuse large B-cell lymphoma accounts for the highest rate of 46.9%. Stage I-II B-cell non-Hodgkin’s lymphoma was 46.9%. Patients treated with R-CHOP for 6-8 cycles accounted for 90.6%. Overall response after 3 months of therapy was 96.9%, complete response accounted for 75%. Overall survival was 85%. Grade I-II anemia was observed in (50%) patients, grade III-IV neutropenia was 12.6%. Grade I elevated liver enzymes (hepatitis) was 12.5%. Nausea, vomiting (37.5%), oral mucositis occurred at mild level (21.9%) and hair loss. Conclusion: The R-CHOP regimen as first-line treatment in CD20(+) B-cell Non-Hodgkin's lymphoma is an effective and well-tolerated approach with low toxicity andability to control effectively, which  increases the complete-response rate and prolongs overall survival.